Spleens of myelofibrosis patients contain malignant hematopoietic stem cells

Journal of Clinical Investigation

Volumn 122, Issue 11, 2012, Pages 3888-3899

  Wang, Xiaoli ^a   Prakash, Sonam ^b   Lu, Min ^a   Tripodi, Joseph ^a   Ye, Fei ^a   Najfeld, Vesna ^a   Li, Yan ^a   Schwartz, Myron ^a   Weinberg, Rona ^c   Roda, Paul ^d   Orazi, Attilio ^b   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d Geisinger/Hazleton Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALE; MOUSE; MYELOFIBROSIS; MYELOFIBROSIS STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN; SPLEEN CELL; STEM CELL;

AGED; ANIMALS; ANTIGENS, CD34; FEMALE; HEMATOPOIESIS, EXTRAMEDULLARY; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASTIC STEM CELLS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIMARY MYELOFIBROSIS; SPLEEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 84868612626     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64397     Document Type: Article

References (47)

1. Hoffman R, Ravandi F. Idiopathic myelofibrosis. In: Hoffman R, et al., eds. Hematology: Basic Principles and Practice. 4th ed. New York, New York, USA: Churchill Livingstone; 2004:1255-1276.
2. Kralovics R, Skoda RC. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005;19(1):1-13. (Pubitemid 39574245)
3. Mesa RA. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002;76(suppl 2):193-203.
4. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272-4290 (Pubitemid 35429665)
5. Prchal JF, Prchal JT. Molecular basis for polycythemia. Curr Opin Hematol. 1999;6(2):100-109. (Pubitemid 29342524)
6. Zhang B, Lewis SM. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. Eur J Haematol. 1989;43(1):63-66. (Pubitemid 19208641)
7. Barosi G, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004;124(5):618-625. (Pubitemid 38297094)
8. Raaijmakers MH, Scadden DT. Evolving concepts on the microenvironmental niche for hematopoietic stem cells. Curr Opin Hematol. 2008;15(4):301-306.
9. Frisch BJ, Porter RL, Calvi LM. Hematopoietic niche and bone meet. Curr Opin Support Palliat Care. 2008;2(3):211-217.
10. Garrett RW, Emerson SG. Bone and blood vessels: the hard and the soft of hematopoietic stem cell niches. Cell Stem Cell. 2009;4(6):503-506.
11. Renström J, Kröger M, Peschel C, Oostendorp RA. How the niche regulates hematopoietic stem cells. Chem Biol Interact. 2010;184(1-2):7-15.
12. Karnoub AE, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2009;449(7162):557-563. (Pubitemid 47525152)
13. McGrail DJ, Ghosh D, Quach ND, Dawson MR. Differential mechanical response of mesenchymal stem cells and fibroblasts to tumor-secreted soluble factors. PLoS One. 2012;7(3):e33248.
14. Klopp AH, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 2007;67(24):11687-11695.
15. James C, et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood. 2008;112(6):2429-2438.
16. Pieri L, Guglielmelli P, Bogani C, Bosi A, Vannucchi AM, Myeloproliferative Disorders Research Consortium (MPD-RC). Mesenchymal stem cells from JAK2 (V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leuk Res. 2008;32(3):516-517. (Pubitemid 351295914)
17. Bacher U, et al. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. Clin Exp Med. 2010;10(3):205-208.
18. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006;108(9):3128-3134.
19. Delhommeau F, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109(1):71-77. (Pubitemid 46053046)
20. Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabeticscid/scid mice. Proc Natl Acad Sci U S A. 1997;94(18):9836-9841. (Pubitemid 27408151)
21. Larochelle A, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med. 1996;2(12):1329-1337.
22. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A. 1997;94(10):5320-5325. (Pubitemid 27214781)
23. Ziegler BL, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science. 1999;285(5433):1553-1558. (Pubitemid 29420577)
24. Wang X, et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 2010;116(26):5972-5982.
25. Barosi G, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98(12):3249-3255.
26. Dick JE. Human stem cell assays in immunedeficient mice. Curr Opin Hematol. 1996;3(6):405-409. (Pubitemid 26408686)
27. Ishii T, et al. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Exp Hematol. 2007;35(11):1633-1640. (Pubitemid 47633770)
28. Tsukamoto N, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol. 1994;86(2):253-258. (Pubitemid 24198985)
29. Risueño RM, et al. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood. 2011;117(26):7112-7120.
30. Eisterer W, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia. 2005;19(3):435-441. (Pubitemid 40403322)
31. Schemionek M, et al. Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. Leukemia. 2012;26(5):1030-1037.
32. Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood. 2001;97(11):3665-3667.
33. Barosi G, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood. 1998;91(10):3630-3636. (Pubitemid 28225729)
34. Cukierman E, Bassi D. The mesenchymal tumor microenvironment: a drug resistant niche. Cell Adh Migr. 2012;6(3):285-296.
35. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep. 2009;4(1):33-40.
36. Martyré MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88(1):9-16. (Pubitemid 24293846)
37. Martyré MC, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997;97(2):441-448.
38. Le Bousse-Kerdilès MC, Martyré MC. Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia: French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin Immunopathol. 1999;21(4):491-508.
39. Wang X, et al. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Exp Hematol. 2009;37(10):1194-1200.
40. Nussenzveig RH, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35(1):32-38.
41. Passamonti F, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
42. Barosi G, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004;124(5):618-625. (Pubitemid 38297094)
43. Thiele J, Pierre R, Imbert M, Vardiman JW, Brunning RD, Glandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris N, Stan N, Vardiman JW, eds. World Health Organization Of Tumors Of Hematopoietic And Lymphoid Tissues. Washington, DC, USA: IARC Press; 2001:35-38.
44. Najfeld V, Coyle T, Berk PD. Transformation of polycythemia vera to acute nonlymphocytic leukemia accompanied by t (1;3)(p36;q21) karyotype. Cancer Genet Cytogenet. 1988;33(2):193-200.
45. Li Z, et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007;282(6):3428-3432. (Pubitemid 47084420)
46. Prakash S, Hoffman R, Barouk S, Wang YL, Knowles DM, Orazi A. Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome- negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Mod Pathol. 2012;25(6):815-827.
47. Sarry JE, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest. 2011;121(1):384-395.